This segment focuses on the research, development, and clinical evaluation of novel therapies for cardiorenal conditions, specifically targeting diseases driven by dysregulated aldosterone. The primary focus is on lorundrostat, a highly selective aldosterone synthase inhibitor (ASI), which is being evaluated in multiple clinical trials for the treatment of hypertension and chronic kidney disease (CKD). Research and development activities include preclinical studies, Phase 2 and Phase 3 clinical trials, and ongoing analysis of clinical data to assess efficacy and safety. The company utilizes advanced methodologies in drug development, including rigorous clinical trial design and data analysis. The patient impact is significant, as these therapies aim to address unmet medical needs in hypertension and CKD, potentially improving patient outcomes and reducing the risk of cardiovascular events. Mineralys Therapeutics aims to establish a strong market position by providing innovative treatments for cardiorenal conditions. Future opportunities include expanding the clinical development program and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and adhering to clinical trial regulations. Partnerships and collaborations are essential for clinical trial execution and commercialization.